In experimental models of atrial fibrillation, HDAC6 inhibition protected against tachypacing-induced contractile dysfunction and electrical remodeling by preserving α-tubulin proteostasis.
Does HDAC6 inhibition prevent contractile dysfunction and atrial remodeling in experimental models of atrial fibrillation?
Inhibition of HDAC6 protects against AF-related atrial remodeling and contractile dysfunction in experimental models, highlighting its potential as a therapeutic target.
BACKGROUND: Atrial fibrillation (AF) is characterized by structural remodeling, contractile dysfunction, and AF progression. Histone deacetylases (HDACs) influence acetylation of both histones and cytosolic proteins, thereby mediating epigenetic regulation and influencing cell proteostasis. Because the exact function of HDACs in AF is unknown, we investigated their role in experimental and clinical AF models. METHODS AND RESULTS: Tachypacing of HL-1 atrial cardiomyocytes and Drosophila pupae hearts significantly impaired contractile function (amplitude of Ca(2+) transients and heart wall contractions). This dysfunction was prevented by inhibition of HDAC6 (tubacin) and sirtuins (nicotinamide). Tachypacing induced specific activation of HDAC6, resulting in α-tubulin deacetylation, depolymerization, and degradation by calpain. Tachypacing-induced contractile dysfunction was completely rescued by dominant-negative HDAC6 mutants with loss of deacetylase activity in the second catalytic domain, which bears α-tubulin deacetylase activity. Furthermore, in vivo treatment with the HDAC6 inhibitor tubastatin A protected atrial tachypaced dogs from electric remodeling (action potential duration shortening, L-type Ca(2+) current reduction, AF promotion) and cellular Ca(2+)-handling/contractile dysfunction (loss of Ca(2+) transient amplitude, sarcomere contractility). Finally, atrial tissue from patients with AF also showed a significant increase in HDAC6 activity and reduction in the expression of both acetylated and total α-tubulin. CONCLUSIONS: AF induces remodeling and loss of contractile function, at least in part through HDAC6 activation and subsequent derailment of α-tubulin proteostasis and disruption of the cardiomyocyte microtubule structure. In vivo inhibition of HDAC6 protects against AF-related atrial remodeling, disclosing the potential of HDAC6 as a therapeutic target in clinical AF.
Zhang et al. (2013) studied Atrial fibrillation. HDAC6 inhibition (tubacin, tubastatin A) vs. Control/Tachypacing alone was evaluated on Contractile dysfunction and electrical remodeling. In experimental models of atrial fibrillation, HDAC6 inhibition protected against tachypacing-induced contractile dysfunction and electrical remodeling by preserving α-tubulin proteostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: